PT  - JOURNAL ARTICLE
AU  - Czeisler, Mark É.
AU  - Capodilupo, Emily R.
AU  - Weaver, Matthew D.
AU  - Czeisler, Charles A.
AU  - Howard, Mark E.
AU  - Rajaratnam, Shantha M.W.
TI  - Prior sleep-wake behavior predicts mental health resilience among adults in the United States during the COVID-19 pandemic
AID  - 10.1101/2021.06.15.21258983
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.15.21258983
4099  - http://medrxiv.org/content/early/2021/06/22/2021.06.15.21258983.short
4100  - http://medrxiv.org/content/early/2021/06/22/2021.06.15.21258983.full
AB  - Rigorous nonpharmaceutical interventions (e.g., stay-at-home orders, remote-work directives) were implemented in early 2020 for coronavirus disease 2019 (COVID-19) pandemic containment in the U.S. During this time, increased sleep duration and delayed sleep timing were reported through surveys (Leone et al., 2021) and wearable data (Rezaei and Grandner, 2021), as were elevated adverse mental health symptom (Czeisler et al., 2020). Inter-relationships between sleep and mental health have not been examined using longitudinal objective sleep-wake data, during these abruptly imposed lifestyle changes.We examined objective sleep-wake data and surveyed mental health data collected among 4,912 U.S. adult users of a validated sleep wearable (WHOOP, Boston, Massachusetts) before and during the COVID-19 pandemic. Comparing the pre-pandemic (January 1 to March 12, 2020) and acute pandemic-onset intervals (March 13 to April 12, 2020), participants exhibited increased mean sleep duration (0.25h [95% CI = 0.237-0.270]), later sleep onset (18m [17.378-20.045]) and offset (36m [35.111-38.106]), and increased consistency of sleep timing (3.51 [3.295-3.728] out of 100); all P < 0.0001. Generally, participants with persistent sleep deficiency and low sleep consistency had higher odds of symptoms of anxiety or depression, burnout, and new or increased substance use during the pandemic. Decreases in sleep duration (adjusted odds ratio [aOR] = 1.30, 95% CI = 1.03-1.65, P = 0.025) and sleep consistency (2.05 [1.17-3.67], P = 0.009) were associated with increased anxiety and depression symptoms during the pandemic. We suggest that sleep duration and consistency may be important predictors of risk of adverse mental health outcomes during a pandemic.M.J. Leone, M. Sigman, D.A. Golombek. Effects of lockdown on human sleep and chronotype during the COVID-19 pandemic. Curr Biol 30(16), R930–R931 (2020).N. Rezaei N, M.A. Grandner. Changes in sleep duration, timing, and variability during the COVID-19 pandemic: Large-scale Fitbit data from 6 major US cities. Sleep Health 10.1016/j.sleh.2021.02.008. (2021).M.É. Czeisler, R.I. Lane, E. Petrosky, et al., Mental Health, Substance Use, and Suicidal Ideation During the COVID-19 Pandemic - United States, June 24-30, 2020. MMWR Morb Mortal Wkly Rep 69(32), 1049–1057 (2020).Significance Statement The coronavirus disease 2019 (COVID-19) pandemic has had profound effects on health, including increased sleep duration and worsened mental health. We examined associations between (1) objective sleep-wake data before and during the COVID-19 pandemic and (2) adverse mental health symptoms and substance use among users of a validated sleep wearable. We found that, in general, participants with persistent sleep deficiency and low sleep consistency had higher odds of symptoms of anxiety or depression, new or increased substance use, and burnout. Our findings suggest that sleep of sufficient duration and consistent timing are associated with mental health resilience, exemplified in this case by the impact of the pandemic and related abrupt lifestyle changes on adverse mental health symptoms.Competing Interest StatementM.É.C., M.D.W., C.A.C., M.E.H., and S.M.W.R. reported receiving a grant from the CDC Foundation with funding from BNY Mellon and a gift from Hopelab, Inc. M.É.C. reported having received a grant from the Australian-American Fulbright Commission administered through a 2020 to 2021 Fulbright Scholarship funded by The Kinghorn Foundation and having received personal fees from Vanda Pharmaceuticals. E.R.C. is a paid employee of and has equity interest in WHOOP, Inc., and has equity interest in ARCHANGELS. M.D.W. reported consulting fees from National Sleep Foundation and the University of Pittsburgh. C.A.C. reported receiving grants to support The COVID-19 Outbreak Public Evaluation (COPE) Initiative and grants from Brigham and Women's Physician's Organization during the conduct of the study; being a paid consultant to or speaker for Ganésco, Institute of Digital Media and Child Development, Klarman Family Foundation, M. Davis and Co, Physician's Seal, Samsung Group, State of Washington Board of Pilotage Commissioners, Tencent Holdings, Teva Pharma Australia, and Vanda Pharmaceuticals, in which C.A.C. holds an equity interest; receiving travel support from Aspen Brain Institute, Bloomage International Investment Group, UK Biotechnology and Biological Sciences Research Council, Bouley Botanical, Dr Stanley Ho Medical Development Foundation, Illuminating Engineering Society, National Safety Council, Tencent Holdings, and The Wonderful Co; receiving institutional research and/or education support from Cephalon, Mary Ann and Stanley Snider via Combined Jewish Philanthropies, Harmony Biosciences, Jazz Pharmaceuticals PLC, Johnson and Johnson, Neurocare, Peter Brown and Margaret Hamburg, Philips Respironics, Regeneron Pharmaceuticals, Regional Home Care, Teva Pharmaceuticals Industries, Sanofi S.A., Optum, ResMed, San Francisco Bar Pilots, Schneider National, Serta, Simmons Betting, Sysco, Vanda Pharmaceuticals; being or having been an expert witness in legal cases, including those involving Advanced Power Technologies; Aegis Chemical Solutions; Amtrak; Casper Sleep; C and J Energy Services; Complete General Construction; Dallas Police Association; Enterprise Rent-A-Car; Steel Warehouse Co; FedEx; Greyhound Lines; Palomar Health District; PAR Electrical, Product, and Logistics Services; Puckett Emergency Medical Services; South Carolina Central Railroad Co; Union Pacific Railroad; UPS; and Vanda Pharmaceuticals; serving as the incumbent of an endowed professorship provided to Harvard University by Cephalon; and receiving royalties from McGraw Hill and Philips Respironics for the Actiwatch-2 and Actiwatch Spectrum devices. C.A.C.'s interests were reviewed and are managed by the Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. S.M.W.R. reported receiving institutional consulting fees from CRC for Alertness, Safety, and Productivity; Teva Pharmaceuticals; Vanda Pharmaceuticals; Circadian Therapeutics; BHP Billiton; and Herbert Smith Freehills; receiving grants from Teva Pharmaceuticals and Vanda Pharmaceuticals; and serving as chair for the Sleep Health Foundation outside the submitted work. M.E.H. reports receiving: institutional consulting fees from Teva Pharmaceuticals, Biogen and Sanofi; and equipment to support research from Optalert and Philips Respironics outside the submitted work. No other potential conflicts of interest were reported.Funding StatementThis work was supported in part by a contract from WHOOP Inc. to Monash University. M.É.C. was supported in part by a 2020-2021 Australian-American Fulbright Scholarship, with funding from The Kinghorn Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Monash University Human Research Ethics Committee (Melbourne, Victoria, Australia) approved the study protocol. WHOOP users agreed to allow their deidentified WHOOP wearable data to be used for research purposes, as outlined in the WHOOP Terms and Conditions document. Participants provided informed electronic consent prior to commencement of the survey. Investigators received anonymized responses, and survey responses were linked with WHOOP wearable data using unique Study Identification codes.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPublic data sharing for these purposes is ethically and legally restricted. The data is collected and used with the consent of individuals who purchase a WHOOP membership (collectively, "WHOOP Members") and agree to the WHOOP terms of use (https://www.whoop.com/termsofuse/) and privacy policy (https://www.whoop.com/privacy/full-privacy-policy/). While WHOOP terms of use and privacy policy permit WHOOP to use collected data that has been aggregated or de-identified in a manner that no longer identifies an individual for informational purposes, analytics or WHOOP's own research purposes, the consent obtained from WHOOP Members does not extend to making the data publicly available for a third party to use for its own purposes. As such, WHOOP's legal department will not permit the data to be shared for these purposes. Data access queries can be directed to the WHOOP Executive team via the Vice President of Performance at WHOOP - Kristen Holmes (holmes@whoop.com).